ARIAD Appoints Chief Legal Officer.Business Editors & Health/Medical Writers CAMBRIDGE, Mass.--(BW HealthWire)--March 12, 2002 ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that Laurie A. Allen, Esq., formerly a partner of the law firm of Brobeck, Phleger & Harrison, LLP LLP - Lower Layer Protocol , was appointed chief legal officer, senior vice president and corporate secretary. In addition to managing the Company's corporate legal activities, she will play a key role in licensing and enforcing ARIAD's broad patent portfolio, with special emphasis on its pioneering NF-(kappa)B technology. Ms. Allen served for the past two years as senior vice president, business development and legal affairs at Alexandria Real Estate Equities, Inc., a real estate investment trust focused on the laboratory market, and practiced law for eight years at Brobeck, Phleger & Harrison, LLP, one of the nation's leading technology law firms. Ms. Allen's law Al·len's law n. The principle that, in contrast to a normal physiology, the more carbohydrate taken by a diabetic, the less carbohydrate is utilized. practice focused on business, securities, and intellectual property matters and managing litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. for life science companies. During 1999, Ms. Allen was senior vice president and general counsel at ARIAD. She earned an L.L.M. in taxation from New York University School of Law The New York University School of Law (NYU Law) is the law school of New York University. Established in 1835, the school offers the J.D., LL.M., and J.S.D. and a J.D. degree from Emory Law School. "Ms. Allen's appointment to our senior management team is further evidence of our assessment of the value of our NF-(kappa)B and other intellectual property assets," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company's development pipeline includes: a drug candidate that controls cell proliferation and nutrient uptake by tumors to treat cancer; a bone-targeted drug candidate to treat the complications of cancer that has spread to bone; a regulated protein therapy product candidate to treat anemia in which the production of erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production is controlled in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. using an orally administered drug; a T cell immunotherapy product candidate in which a non-immunosuppressive drug may be used to treat graft-vs-host disease following donor bone marrow transplantation Bone Marrow Transplantation Definition The bone marrow—the sponge-like tissue found in the center of certain bones—contains stem cells that are the precursors of white blood cells, red blood cells, and platelets. - a therapy for cancer and other immune and blood diseases; and dual-action drug candidates that block bone resorption and stimulate bone formation to treat osteoporosis. ARIAD also has an exclusive license to pioneering technology related to the discovery, development, and use of drugs that modulate the NF-(kappa)B pathway, which has been implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in many major diseases. Additional information about ARIAD can be found on the web at www.ariad.com, including a new Chairman's View on the Company's product development partnering strategy, which is not made a part of this press release. Some of the matters discussed herein are forward-looking statements. Such statements are identified by the use of words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied in such statements. These risks include, but are not limited to, risks and uncertainties regarding the Company's preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. , the Company's ability to conduct clinical trials of its product candidates and the results of such trials, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on the Company's collaborators and other factors. These risks are identified in ARIAD's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 2000, filed with the Securities and Exchange Commission. The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion